Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYR | P14679 | 3/20 | 0.46 |
| ▸ | ATP1A1 | P05023 | 1/20 | 0.38 |
| ▸ | ATP1B1 | P05026 | 1/20 | 0.38 |
| ▸ | ATP1A3 | P13637 | 1/20 | 0.38 |
| ▸ | ATP1B2 | P14415 | 1/20 | 0.38 |
| ▸ | ATP1A2 | P50993 | 1/20 | 0.38 |
| ▸ | ATP1B3 | P54709 | 1/20 | 0.38 |
| ▸ | FXYD2 | P54710 | 1/20 | 0.38 |
| ▸ | ATP1A4 | Q13733 | 1/20 | 0.38 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Argentatine A SCHEMBL18495437 | 0.87 | TYR (0.48) | TYRATP1A1ATP1B1ATP1A3ATP1B2 | |
| Argentatine A SCHEMBL20888305 | 0.87 | TYR (0.48) | TYRATP1A1ATP1B1ATP1A3ATP1B2 | |
| Argentatine A SCHEMBL20279380 | 0.87 | TYR (0.48) | TYRATP1A1ATP1B1ATP1A3ATP1B2 | |
| Argentatine A SCHEMBL29732482 | 0.87 | TYR (0.48) | TYRATP1A1ATP1B1ATP1A3ATP1B2 | |
| Argentatine A SCHEMBL18495439 | 0.87 | TYR (0.48) | TYRATP1A1ATP1B1ATP1A3ATP1B2 | |
| Argentatine A SCHEMBL30836078 | 0.87 | TYR (0.48) | TYRATP1A1ATP1B1ATP1A3ATP1B2 | |
| SCHEMBL20888304 | 0.81 | TYR (0.49) | TYRATP1A1ATP1B1ATP1A3ATP1B2 | |
| SCHEMBL22787150 | 0.81 | TYR (0.46) | TYRABCB1 | |
| SCHEMBL22787125 | 0.81 | TYR (0.46) | TYRABCB1 | |
| SCHEMBL18197925 | 0.81 | TYR (0.51) | TYRATP1A1ATP1B1ATP1A3ATP1B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210369738-A1 | PRODUCTION METHOD OF TELOMERASE ACTIVATORS AND TELOMERASE ACTIVATORS OBTAINED BY THIS METHOD | IZMIR YUKSEK TEKNOLOJI ENSTITUSU (TR) | 2021-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210369738-A1 | PRODUCTION METHOD OF TELOMERASE ACTIVATORS AND TELOMERASE ACTIVATORS OBTAINED BY THIS METHOD | TERT, TERB1, TERF2 | TYR 455/4885ATP1A1 2940/4885ATP1B1 2469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.